Trial · NCT00585195
Results by group400
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 400
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 50 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 100 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 200 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 200 mg BID | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 250 mg BID | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 300 mg BID | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | High Dose Escalation Cohort: Crizotinib 300 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | High Dose Escalation Cohort: Crizotinib 400 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | High Dose Escalation Cohort: Crizotinib 500 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | High Dose Escalation Cohort: Crizotinib 650 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib | High Dose Escalation Cohort: Crizotinib 800 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 50 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 100 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 200 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 200 mg BID | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 250 mg BID | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | Low Dose Escalation Cohort: Crizotinib 300 mg BID | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | High Dose Escalation Cohort: Crizotinib 300 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | High Dose Escalation Cohort: Crizotinib 400 mg QD | 250 | milligram | ||
| Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib | High Dose Escalation Cohort: Crizotinib 500 mg QD | 250 | milligram |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00585195/results